Product Information
FEBUXOSTAT 40 MG TABLET is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.1911 per EA under NDC 00054041313. Its NADAC has been published 356 times since Dec 11, 2019.
FDA first approved this application on Oct 15, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054041313
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FEBUXOSTATApproval Type
Generic (ANDA)
FDA Application
ANDA205414FDA Approved
10/15/2019
TE Code
AB
On Market Since
11/11/2019
Pharmacological Classes
Price Statistics
The NADAC for FEBUXOSTAT 40 MG TABLET has been published 356 times since Dec 11, 2019, and over the history we have for it it has declined 96.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1911 per EA |
|---|---|
| All-time high | $5.7102 (Dec 11, 2019) |
| All-time low | $0.1911 (Sep 23, 2026) |
| 52-week high | $0.2464 |
| 52-week low | $0.1911 |
| Median price | $0.6324 |
| Average price | $0.9639 |
| Largest weekly change | -33.0% (Apr 22, 2020) |
| Weeks tracked | 356 |
| Tracking since | Dec 11, 2019 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Febuxostat market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Xanthine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FEBUXOSTAT 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FEBUXOSTAT 40 MG TABLET, manufactured by Hikma Pharmaceuticals USA Inc., is $0.1911 per EA (NDC 00054041313), effective Sep 30, 2026.
How has the price of FEBUXOSTAT 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for FEBUXOSTAT 40 MG TABLET has declined 96.7%. It has been tracked across 356 weekly CMS publications since Dec 11, 2019.
What are the highest and lowest recorded NADAC prices for FEBUXOSTAT 40 MG TABLET?
Since Dec 11, 2019, the NADAC for FEBUXOSTAT 40 MG TABLET has ranged from a low of $0.1911 (Sep 23, 2026) to a high of $5.7102 (Dec 11, 2019), with a median of $0.6324 per EA.
Are there cheaper alternatives to FEBUXOSTAT 40 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FEBUXOSTAT 40 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures FEBUXOSTAT 40 MG TABLET?
FEBUXOSTAT 40 MG TABLET (NDC 00054041313) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.